Omnipaque Versus Gastroview as Oral Contrast for Abdominal and Pelvic CT
Status:
Completed
Trial end date:
2009-03-01
Target enrollment:
Participant gender:
Summary
Patients who are scheduled by their health care provider for routine computed tomography (CT)
scan will be asked to participate in this study. The primary purpose is to determine if there
is a difference in patient preference for Omnipaque versus Gastroview as oral contrast for
abdominal pelvic CT. A secondary objective is to evaluate if there is significant difference
in bowel opacification for the two agents.